

Disclosures

Personal Commercial (7)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|-----------------------------|--|--------------------------|--|
| <i>Self</i> | | | |
| Abbott Laboratories | Consultant Fees/Honoraria | Modest (< \$5,000) | Acute Coronary Syndromes Stable Ischemic Heart Disease |
| Acist Medical | Consultant Fees/Honoraria | Modest (< \$5,000) | Stable Ischemic Heart Disease |
| AstraZeneca Pharmaceuticals | Research/Research Grants | Significant (>= \$5,000) | Acute Coronary Syndromes |
| Auxilius Pharma | Other - Consultant | None (\$0) | Stable Ischemic Heart Disease |
| GSK | Research/Research Grants ‡ SofTMech | Significant (>= \$5,000) | Noninvasive Imaging |
| HeartFlow | Consultant Fees/Honoraria | Significant (>= \$5,000) | Noninvasive Imaging |
| Novartis Corporation | Research/Research Grants ‡ Study of the Vascular Effects of Serelaxin; NCT01979614 | Significant (>= \$5,000) | General Cardiology |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (9)

| Trial Name | Trial Sponsor | Trial Funding Source |
|--|--------------------------------------|----------------------------|
| Global Leaders; NCT01813435 | Biosensors International | Biosensors |
| Leaders Free; NCT01623180 | Biosensors International | Biosensors International |
| EVOLVE | Boston Scientific International S.A. | |
| Edify Heart Failure with Preserved Ejection Fraction – CL2-16257-101 | InspireMD | |
| MASTER II Trial (V6.0) | INSPIRE-MD | |
| AMICI; NCT01781390 | Mesoblast, Ltd. | Mesoblast, Ltd. |
| CATCH-AMI; NCT01905475 | Polyphor Ltd. | Polyphor Ltd. |
| FAME-3; NCT02100722 | Stanford University | St Jude Medical; Medtronic |
| RIPCORD-2 | University of Southampton | BostonScientific |

Institutional Financial Decision-Making Role (1)

| Funding Source | Institutional Compensation Level |
|---------------------|----------------------------------|
| Abbott Laboratories | Significant (>= \$5,000) |

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 12/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 12/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 12/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 12/3/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.